Clinical characteristics and risk factors for mortality in cefepime-resistant Pseudomonas aeruginosa bacteremia

Journal of Microbiology, Immunology and Infection

Volumn 48, Issue 2, 2015, Pages 175-182

  Su, Ting Yi ^a   Ye, Jung Jr ^a   Hsu, Po Chang ^a   Wu, Hsuan Feng ^a   Chia, Ju Hsin ^b,c   Lee, Ming Hsun ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Bacteremia; Cefepime resistant; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE;

AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; BLOOD CULTURE; CHARLSON COMORBIDITY INDEX; DIABETES MELLITUS; FEMALE; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; HYPERTENSION; INTENSIVE CARE UNIT; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PSEUDOMONAS INFECTION; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; URINARY TRACT INFECTION; VENTILATOR; ADULT; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PSEUDOMONAS AERUGINOSA; SEVERITY OF ILLNESS INDEX; SURVIVAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAM RESISTANCE; CEPHALOSPORINS; FEMALE; HUMANS; MALE; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 84924621522     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2013.07.009     Document Type: Article

References (30)

1. Cosgrove S.E., Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 2003, 36:1433-1437.
2. Klevens R.M., Edwards J.R., Gaynes R.P. National Nosocomial Infections Surveillance System. The impact of antimicrobial-resistant, health care-associated infections on mortality in the United States. Clin Infect Dis 2008, 47:927-930.
3. Osmon S., Ward S., Fraser V.J., Kollef M.H. Hospital mortality for patients with bacteremia due to Staphylococcus aureus or Pseudomonas aeruginosa. Chest 2004, 125:607-616.
4. Harris A., Torres-Viera C., Venkataraman L., DeGirolami P., Samore M., Carmeli Y. Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. Clin Infect Dis 1999, 28:1128-1133.
5. Bonomo R.A., Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 2006, 43:S49-S56.
6. Carmeli Y., Troillet N., Karchmer A.W., Samore M.H. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 1999, 159:1127-1132.
7. Livermore D.M. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?. Clin Infect Dis 2002, 34:634-640.
8. Croughs P.D., Li B., Hoogkamp-Korstanje J.A., Stobberingh E. Antibiotic Resistance Surveillance Group. Thirteen years of antibiotic susceptibility surveillance of Pseudomonas aeruginosa from intensive care units and urology services in the Netherlands. Eur J Clin Microbiol Infect Dis 2013, 32:283-288.
9. Akhabue E., Synnestvedt M., Weiner M.G., Bilker W.B., Lautenbach E. Cefepime-resistant Pseudomonas aeruginosa. Emerg Infect Dis 2011, 17:1037-1043.
10. Henry D.A., Speert D.P. Pseudomonas. Manual of clinical microbiology 2011, 677-691. American Society of Microbiology, Washington, DC. 10th ed. J. Versalovic, K.C. Carroll, G. Funke, J.H. Jorgensen, M.L. Landry, D.W. Warnock (Eds.).
11. Performance standards for antimicrobial susceptibility testing: Twenty-second informational supplement. (CLSI document M100-S22) 2012, Clinical and Laboratory Standards Institute, CLSI, Wayne, PA.
12. Ohmagari N., Hanna H., Graviss L., Hackett B., Perego C., Gonzalez V., et al. Risk factors for infections with multidrug-resistant Pseudomonas aeruginosa in patients with cancer. Cancer 2005, 104:205-212.
13. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39:S1-S266. National Kidney Foundation.
14. Mermel L.A., Allon M., Bouza E., Craven D.E., Flynn P., O'Grady N.P., et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 49:1-45.
15. Chow J.W., Fine M.J., Shlaes D.M., Quinn J.P., Hooper D.C., Johnson M.P., et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991, 115:585-590.
16. Charlson M., Szatrowski T.P., Peterson J., Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994, 47:1245-1251.
17. Morata L., Cobos-Trigueros N., Martínez J.A., Soriano A., Almela M., Marco F., et al. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2012, 56:4833-4837.
18. Tam V.H., Rogers C.A., Chang K.T., Weston J.S., Caeiro J.P., Garey K.W. Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob Agents Chemother 2010, 54:3717-3722.
19. Aloush V., Navon-Venezia S., Seigman-Igra Y., Cabili S., Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 2006, 50:43-48.
20. Cao B., Wang H., Sun H., Zhu Y., Chen M. Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. J Hosp Infect 2004, 57:112-118.
21. Joo E.J., Kang C.I., Ha Y.E., Kang S.J., Park S.Y., Chung D.R., et al. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome. Microb Drug Resist 2011, 17:305-312.
22. Hirsch E.B., Cottreau J.M., Chang K.T., Caeiro J.P., Johnson M.L., Tam V.H. A model to predict mortality following Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis 2012, 72:97-102.
23. Peña C., Suarez C., Gozalo M., Murillas J., Almirante B., Pomar V., et al. Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections. Antimicrob Agents Chemother 2012, 56:1265-1272.
24. Kang C.I., Kim S.H., Kim H.B., Park S.W., Choe Y.J., Oh M.D., et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 2003, 37:745-751.
25. Micek S.T., Lloyd A.E., Ritchie D.J., Reichley R.M., Fraser V.J., Kollef M.H. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005, 49:1306-1311.
26. Kang C.I., Kim S.H., Park W.B., Lee K.D., Kim H.B., Kim E.C., et al. Bloodstream infections caused by antibiotic-resistant Gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005, 49:760-766.
27. Lodise T.P., Patel N., Kwa A., Graves J., Furuno J.P., Graffunder E., et al. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother 2007, 51:3510-3515.
28. Martínez J.A., Cobos-Trigueros N., Soriano A., Almela M., Ortega M., Marco F., et al. Influence of empiric therapy with a beta-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to Gram-negative microorganisms. Antimicrob Agents Chemother 2010, 54:3590-3596.
29. Peña C., Suarez C., Ocampo-Sosa A., Murillas J., Almirante B., Pomar V., et al. Effect of adequate single-drug vs combination antimicrobial therapy on mortality in Pseudomonas aeruginosa bloodstream infections: a post hoc analysis of a prospective cohort. Clin Infect Dis 2013, 57:208-216.
30. Bowers D.R., Liew Y.X., Lye D.C., Kwa A.L., Hsu L.Y., Tam V.H. Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2013, 57:1270-1274.